This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Xeljanz®(tofacitinib citrate) Prescribing information, Enbrel®(etanercept) Prescribing information, Inflectra®(infliximab) prescribing information and Maxtrex(methotrexate) Prescribing information. Adverse event reporting can be found at the bottom of the page.
Rheumatoid arthritis (RA) is a type of chronic inflammatory autoimmune disease.1
Autoimmune diseases are those in which the immune system mistakenly attacks the cells of the body.2 (The prefix “auto,” meaning self, refers to how the immune system attacks the body ie, the “self”.)3
This is different from the typical function of the immune system, which is to attack pathogens such as bacteria and viruses, and unhealthy cells like those damaged by the sun, to protect the body.4
For patients with RA, the autoimmune response primarily affects the joints, manifesting as joint inflammation.1,5 Symptoms include swelling and tenderness in the joints, commonly those of the fingers, with smaller joints typically being affected before larger joints.1,5 Overall, the inflammation caused by RA can lead to progressive destruction of joints and joint deformity, especially if left untreated.1,5,6
Although it primarily affects the joints, RA is a systemic disease, meaning that the whole body can be affected.5 Patients may show involvement of other organs such as the heart and lungs.2 Altogether, RA can lead to difficulty with everyday functioning and increased mortality.7
Below are typical signs and symptoms of RA, which range from symptoms within the joints to whole body symptoms.
Here are some key demographic characteristics of Rheumatoid arthritis
RA has been estimated to affect 0.5% to 1% of adults in developed countries.8 Globally, RA has been estimated to affect 0.24% of the population.9
RA affects approximately twice as many women as men.9,10,11
New cases of RA have been found to be highest in women between 45 and 74 years and men over 65, although RA can begin at any age.11 There is even a juvenile form of RA.8
1.Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010; 69:1580-1588.
2.Rheumatoid Arthritis. Centers for Disease Control and Prevention [Document on the Internet]. 2018 Apr 3 [cited 2018 Aug 15]. Available from: https://www.cdc.gov/arthritis/basics/rheumatoid-arthritis.html
3.Stedman’s medical dictionary for the health profession and nursing: Baltimore Maryland: Lippincott Williams & Wilkins. Illustrated 5th ed. 2005.
4.Overview of the Immune System. National Institute of Allergy and Infectious Diseases [Document on the Internet]. 2018 [cited 2018 Aug 15]. Available from: https://www.niaid.nih.gov/research/immune-system-overview
5.Khurana R, Berney SM. Clinical aspects of rheumatoid arthritis. Pathophysiology. 2005; 12:153-165.
6.Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76:960-977.
7.Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2015; Special Article. doi:10.1002/acr.22783.
8.Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009; 11(3):229. doi:10.1186/ar2669.
9.Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014; 73:1316-1322.
10.Eriksson JK, Neovius M, Ernestam S, Lindblad S, Simard JF, Askling J. Incidence of rheumatoid arthritis in Sweden: a nationwide population-based assessment of incidence, its determinants, and treatment penetration. Arthritis Care Res. 2013; 65(6):870-878.
11.Humphreys JH, Verstappen SMM, Hyrich KL, Chipping JR, Marshal T, Symmons DPM. The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria: results from the Norfolk Arthritis Register. Ann Rheum Dis. 2013; 72:1315-1320.
Click below to view the Immuno-navigator tool. An interactive tool to help you manage discussions with your patients .
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021